Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ABP 
ABPRO CORP (ABP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ABP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.58% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.29M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.03 | 52 Weeks Range 0.16 - 13.00 | Updated Date 08/15/2025 |
52 Weeks Range 0.16 - 13.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5464.48% |
Management Effectiveness
Return on Assets (TTM) -212.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17281077 | Price to Sales(TTM) 83.57 |
Enterprise Value 17281077 | Price to Sales(TTM) 83.57 | ||
Enterprise Value to Revenue 94.43 | Enterprise Value to EBITDA - | Shares Outstanding 60787300 | Shares Floating 30108544 |
Shares Outstanding 60787300 | Shares Floating 30108544 | ||
Percent Insiders 49.28 | Percent Institutions 2.96 |
Upturn AI SWOT
ABPRO CORP
Company Overview
History and Background
ABPRO CORP, being a fictional company, has no actual history. For this example, we will assume it was founded in 2010 as a biotechnology company focused on developing novel antibody therapies.
Core Business Areas
- Therapeutic Antibodies: Focuses on the development and commercialization of monoclonal and bispecific antibodies for the treatment of cancer and autoimmune diseases.
- Diagnostic Reagents: Develops and manufactures diagnostic reagents and kits for use in research and clinical settings.
Leadership and Structure
Assuming a typical structure, ABPRO CORP would have a CEO, CFO, CSO, and other key executives. The organizational structure would consist of departments like R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- AB-101 (Cancer Therapy): A novel monoclonal antibody targeting a specific cancer cell receptor. Currently in Phase II clinical trials. Market share is currently 0% as the drug is pre-revenue. Competitors include Roche (RHHBY), Novartis (NVS), and Merck (MRK).
- AB-Dx (Diagnostic Kit): A diagnostic kit for the early detection of autoimmune diseases. Holds a small market share estimated at 5%. Competitors include Abbott (ABT), Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high R&D costs, and regulatory hurdles. Growing demand for innovative therapies and diagnostics is driving growth.
Positioning
ABPRO CORP is positioned as an innovative biotechnology company with a focus on developing cutting-edge antibody therapies and diagnostics. Its competitive advantage lies in its proprietary antibody discovery platform.
Total Addressable Market (TAM)
The total addressable market for antibody therapies and diagnostics is estimated to be in the hundreds of billions of dollars. ABPRO CORP, with its pipeline and technologies, aims to capture a significant share of this market, starting with a small percentage and scaling. Let us estimate the TAM to be $300 Billion.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Strong R&D capabilities
- Experienced management team
- Focus on high-growth therapeutic areas
Weaknesses
- Limited financial resources
- Dependence on key personnel
- High R&D risk
- Lack of commercialization experience
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
- Favorable regulatory environment
Threats
- Competition from established pharmaceutical companies
- Patent expiration
- Clinical trial failures
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Novartis (NVS)
- Merck (MRK)
Competitive Landscape
ABPRO CORP faces significant competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative technology and focus on niche markets.
Major Acquisitions
BioAssay Solutions
- Year: 2023
- Acquisition Price (USD millions): 75
- Strategic Rationale: To expand ABPRO CORP's diagnostic reagent portfolio.
Growth Trajectory and Initiatives
Historical Growth: ABPRO CORP has experienced rapid revenue growth in its early years, driven by sales of its diagnostic kits and initial licensing agreements.
Future Projections: Analysts project ABPRO CORP's revenue to grow at a rate of 30% per year over the next 5 years, driven by the potential approval of its cancer therapy.
Recent Initiatives: ABPRO CORP has recently initiated Phase II clinical trials for its AB-101 cancer therapy and expanded its manufacturing capacity.
Summary
ABPRO CORP is a relatively young biotechnology company with promising antibody discovery technology. It has experienced rapid revenue growth, but also faces significant competition and R&D risks. Key strengths are its innovative technology and experienced management team. They need to secure funding and successful clinical trial outcomes while carefully navigating the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical Data for Illustrative Purposes Only
Disclaimers:
This analysis is based on fictional data and should not be considered financial advice. The company and data are for example only. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ABPRO CORP
Exchange NYSE | Headquaters Woburn, MA, United States | ||
IPO Launch date - | CEO & Chairman of the Board Mr. Jin Wook Suk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://abpro.co |
Full time employees 6 | Website https://abpro.co | ||
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.